AstraZeneca and Bristol Myers Squibb Held Early Stage Combination Talks With No Deal Confirmed
More in Markets & Finance
- Palantir Q2 2026 Revenue Reached $1.935 Billion on 93% Annual Growth
- Sterling Infrastructure Q2 Revenue Hits $1.17 Billion With 50% Organic Growth and Raised Full-Year Guidance
- Jazz Pharmaceuticals Posts Record $1.21 Billion Quarter on Oncology and Sleep Drug Growth
- Onsemi Q2 2026 Revenue Reaches $1.60 Billion as Free Cash Flow Margin Expands to 27%
- Strategy Repurchases 912,143 STRC Preferred Shares for $81.2 Million Using Bitcoin and MSTR Proceeds
- Ardent Health Q2 2026 Net Income Falls 77 Percent as Revenue Dips 1.4 Percent
- Talos Energy Posts 664.8 Million in Q2 Revenue and Raises Full Year Production Guidance
- Parker-Hannifin Reports Full Year Fiscal 2026 Results on August 6
- Cogent Communications Sets August 6 Date for Q2 2026 Results Release